A
study found that sustained weight loss protects against breast cancer and the
FDA's approval of a new use for Keytruda
A
recent study found that women over 50 who lost weight and kept it off for more
than 8 years had a lower risk of breast cancer, offering clinicians even
another incentive to advise their patients to reduce weight and keep it off.
This was one of the top stories in oncology last week.
Another
top story was the news that an FDA advisory committee voted to recommend the
approval of Keytruda for patients with high-risk bladder cancer.
Breast
cancer risk is reduced by sustained weight loss
Compared to women whose weight stayed unchanged, women aged 50 and older who had sustained weight loss for more than 8 years had a lower risk of breast cance
Scale
According
to the findings, women aged 50 and older who had maintained weight loss for
more than 8 years had a lower risk of breast cancer than women whose weight
remained unchanged.
An
FDA advisory committee has recommended that Keytruda be approved for the
treatment of high-risk bladder cancer
Patients
with bacillus Calmette-Guérin-unresponsive, high-risk, no muscle-invasive
bladder cancer with carcinoma in situ with or without papillary tumours who are
ineligible for or have chosen not to undergo cystectomy will benefit from
pembrolizumab, according to an FDA advisory group.
In
early-stage triple-negative breast cancer, circulating tumour DNA predicts
recurrence
According
to preplanned analyses of results from the randomised phase 2 BRE12-158 trial
presented at the San Antonio Breast Cancer Symposium, detection of circulating
tumour DNA after neoadjuvant chemotherapy appeared to independently predict
disease recurrence among women with early-stage triple-negative breast cancer.
In
advanced multiple myeloma, a daratumumab-based triplet combination improves
PFS
According
to results of the randomised phase 3 CANDOR trial presented during the
late-breaking abstract session of the ASH Annual Meeting and Exposition, a
novel triple-agent combination of carfilzomib, dexamethasone, and daratumumab
outperformed carfilzomib plus dexamethasone in terms of PFS and overall
response rate among patients with relapsed or refractory multiple myeloma.
Tucatinib
has been designated as a breakthrough therapy by the FDA for advanced breast
cancer
According
to a press release from the agent's producer, the FDA has given tucatinib, in
combination with trastuzumab and capecitabine, breakthrough therapy designation
for the treatment of locally advanced unresectable or metastatic HER2-positive
breast cancer.